Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis. [PDF]
Ther Adv Respir DisBlankenship S +6 more
europepmc +1 more source
Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis. [PDF]
Endocr ConnectEdlund A +3 more
europepmc +1 more source
Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease. [PDF]
World J GastroenterolLee J +11 more
europepmc +1 more source
Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis. [PDF]
J Cosmet DermatolSmith AD +5 more
europepmc +1 more source
The evolving understanding of cystic fibrosis-related diabetes in the highly effective modulator therapy era: a scoping review. [PDF]
DiabetologiaSharpe H, Lam GY.
europepmc +1 more source
Beyond F508del: equity as the next frontier in cystic fibrosis. [PDF]
Lancet Reg Health AmCohen RWF +7 more
europepmc +1 more source
ABCB4 disease-causing variants S242R, S346I, T437I and T1077M significantly impair its function and display differential sensitivity to potentiators. [PDF]
Sci RepMadry C +13 more
europepmc +1 more source
Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]
Pediatr PulmonolKümmerli S +6 more
europepmc +1 more source